{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Marginal+Zone+B+Cell+Lymphoma%29",
    "query": {
      "condition": "Marginal Zone B Cell Lymphoma)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "local",
  "last_synced_at": "2026-05-21T05:22:16.837Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03314974",
      "title": "Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acquired Bone Marrow Failure Syndromes",
        "Acute Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Acute Myeloid Leukemia",
        "Biphenotypic/Undifferentiated/Prolymphocytic Leukemias",
        "Burkitt Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Chronic Myelogenous Leukemia",
        "Diffuse Large Cell Non Hodgkins Lymphoma",
        "Follicular Lymphoma",
        "High Grade Non-Hodgkin's Lymphoma, Adult",
        "High Risk Anemia",
        "Juvenile Myelomonocytic Leukemia",
        "Lymphoblastic Lymphoma",
        "Lymphoma",
        "Lymphoplasmacytic Lymphoma",
        "MRD Positive Leukemia",
        "Mantle-Cell Lymphoma",
        "Marginal Zone B-Cell Lymphoma",
        "Multiple Myeloma",
        "Myelodysplasia",
        "Myelofibrosis",
        "Myeloproliferative Neoplasms",
        "Natural Killer Cell Malignancies",
        "Plasma Cell Leukemia",
        "Prolymphocytic Leukemia",
        "Refractory Anemia",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "HSCT with Non-TBI Regimen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HSCT with TBI Regimen",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "Up to 60 Years"
      },
      "enrollment_count": 300,
      "start_date": "2018-03-30",
      "completion_date": "2027-06-10",
      "has_results": false,
      "last_update_posted_date": "2025-06-24",
      "last_synced_at": "2026-05-21T04:56:35.336Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03314974"
    },
    {
      "nct_id": "NCT01962636",
      "title": "Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute Lymphocytic Leukemia (ALL)",
        "Acute Myeloid Leukemia (AML)",
        "Burkitt's Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Chronic Myelogenous Leukemia",
        "Diffuse Large B Cell Lymphoma",
        "Follicular Lymphoma",
        "Lymphoblastic Lymphoma",
        "Lymphoplasmacytic Lymphoma",
        "Mantle-Cell Lymphoma",
        "Marginal Zone B-Cell Lymphoma",
        "Multiple Myeloma",
        "Myelodysplasia",
        "Myelofibrosis",
        "Non-Hodgkin Lymphoma",
        "Plasma Cell Leukemia",
        "Prolymphocytic Leukemia",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine A",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Mycophenylate mofetil",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Umbilical cord blood",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "Up to 55 Years"
      },
      "enrollment_count": 200,
      "start_date": "2016-12",
      "completion_date": "2026-05-14",
      "has_results": false,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-05-21T05:22:16.837Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01962636"
    },
    {
      "nct_id": "NCT03919175",
      "title": "Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Follicular Lymphoma",
        "Follicular Lymphoma Grade 2",
        "Follicular Lymphoma Grade IIIa",
        "Follicular Lymphoma, Grade 1",
        "Lymphoma",
        "Marginal Zone B Cell Lymphoma",
        "Marginal Zone Lymphoma"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Umbralisib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2019-09-01",
      "completion_date": "2024-05-05",
      "has_results": true,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-05-16T12:20:35.769Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03919175"
    },
    {
      "nct_id": "NCT02722668",
      "title": "UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Leukemia",
        "Acute Lymphoblastic Leukemia/Lymphoma",
        "Acute Myeloid Leukemia",
        "Biphenotypic/Undifferentiated/Prolymphocytic Leukemias",
        "Bone Marrow Failure Syndromes",
        "Burkitt's Lymphoma",
        "Chronic Myelogenous Leukemia",
        "Follicular Lymphoma",
        "Hodgkin Lymphoma",
        "Large-cell Lymphoma",
        "Leukemia or MDS in Aplasia",
        "Lymphoplasmacytic Lymphoma",
        "MRD Positive Leukemia",
        "Mantle-cell Lymphoma",
        "Marginal Zone B-cell Lymphoma",
        "Multiple Myeloma",
        "Myelodysplastic Syndrome",
        "Myeloproliferative Neoplasms/Myelofibrosis",
        "Natural Killer Cell Malignancies",
        "Plasma Cell Leukemia",
        "Prolymphocytic Leukemia",
        "Relapsed Chronic Lymphocytic Leukemia",
        "Relapsed Multiple Myeloma",
        "Relapsed Small Lymphocytic Lymphoma",
        "Relapsed T-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "ATG",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "MMF",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "TBI",
          "type": "RADIATION"
        },
        {
          "name": "Umbilical cord blood cell infusion",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "Up to 75 Years"
      },
      "enrollment_count": 15,
      "start_date": "2017-05-15",
      "completion_date": "2024-02-22",
      "has_results": true,
      "last_update_posted_date": "2025-07-04",
      "last_synced_at": "2026-05-19T23:28:53.160Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02722668"
    },
    {
      "nct_id": "NCT02914938",
      "title": "A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia (CLL)",
        "Diffuse Large B-cell Lymphoma (DLBCL)",
        "Follicular Lymphoma (FL)",
        "High Grade Non-Hodgkin's Lymphoma",
        "Mantle Cell Lymphoma (MCL)",
        "Marginal Zone B Cell Lymphoma",
        "Small Lymphocytic Lymphoma (SLL)"
      ],
      "interventions": [
        {
          "name": "ME-401",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Zanubrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MEI Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 97,
      "start_date": "2016-10",
      "completion_date": "2023-03-29",
      "has_results": false,
      "last_update_posted_date": "2023-05-09",
      "last_synced_at": "2026-05-05T11:00:14.353Z",
      "location_count": 23,
      "location_summary": "Tucson, Arizona • Corona, California • Miami, Florida + 18 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Corona",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02914938"
    },
    {
      "nct_id": "NCT00783367",
      "title": "Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Follicular Lymphoma",
        "Lymphoma of Mucosa-Associated Lymphoid Tissue",
        "Lymphoma, Small Lymphocytic",
        "MALT Lymphoma",
        "Mantle-Cell Lymphoma",
        "Marginal Zone B-Cell Lymphoma",
        "Waldenstrom Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2008-07",
      "completion_date": "2020-11-23",
      "has_results": true,
      "last_update_posted_date": "2023-03-30",
      "last_synced_at": "2026-04-30T16:12:00.024Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00783367"
    },
    {
      "nct_id": "NCT02991898",
      "title": "Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Acute Myelogenous Leukemia",
        "Biphenotypic Leukemia",
        "Burkitt Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Chronic Myelogenous Leukemia",
        "Follicular Lymphoma",
        "Hodgkin Lymphoma",
        "Large-cell Lymphoma",
        "Lymphoplasmacytic Lymphoma",
        "Mantle-Cell Lymphoma",
        "Marginal Zone B-Cell Lymphoma",
        "Multiple Myeloma",
        "Myelodysplastic Syndromes",
        "Natural Killer Cell Malignancies",
        "Prolymphocytic Leukemia",
        "Small Lymphocytic Lymphoma",
        "Undifferentiated Leukemia"
      ],
      "interventions": [
        {
          "name": "Infusion of Treg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 3,
      "start_date": "2017-02-16",
      "completion_date": "2019-06-20",
      "has_results": true,
      "last_update_posted_date": "2020-09-29",
      "last_synced_at": "2026-05-05T19:17:54.277Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02991898"
    },
    {
      "nct_id": "NCT01460134",
      "title": "A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Any T-cell Malignancy",
        "Burkett's Lymphoma",
        "CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Colorectal Adenocarcinoma, Non-small Cell Lung Cancer)",
        "Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer",
        "Mantle Cell Lymphoma",
        "Marginal Zone B Cell Lymphoma)",
        "Primary Lymphoma of the Central Nervous System",
        "Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "CDX-1127",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celldex Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2011-10",
      "completion_date": "2017-10-16",
      "has_results": false,
      "last_update_posted_date": "2018-01-31",
      "last_synced_at": "2026-05-20T04:21:44.905Z",
      "location_count": 10,
      "location_summary": "Scottsdale, Arizona • Stanford, California • Rochester, Minnesota + 7 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01460134"
    },
    {
      "nct_id": "NCT01163201",
      "title": "T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphocytic Leukemia",
        "Acute Myeloid Leukemia",
        "Anemia, Refractory, With Excess of Blasts",
        "Burkitt's Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Chronic Myelogenous Leukemia in Blast Crisis",
        "Chronic Myeloproliferative Disease",
        "Follicular Lymphoma",
        "Hematologic Malignancy",
        "High Grade Non-Hodgkin's Lymphoma",
        "Large Cell Non-Hodgkin's Lymphoma",
        "Lymphoblastic Lymphoma",
        "Lymphoplasmacytic Lymphoma",
        "Mantle-Cell Lymphoma",
        "Marginal Zone B-cell Lymphoma",
        "Prolymphocytic Lymphoma",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "CD3+ Teff cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Total body irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Treg cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Umbilical cord blood transplantation",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 0,
      "start_date": "2014-01",
      "completion_date": "2015-01",
      "has_results": false,
      "last_update_posted_date": "2017-12-02",
      "last_synced_at": "2026-05-05T19:17:54.277Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01163201"
    },
    {
      "nct_id": "NCT02086591",
      "title": "A Phase II Study of Doxycycline in Relapsed NHL",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Diffuse Large B-Cell Lymphoma",
        "Chronic Lymphocytic Leukemia (CLL)",
        "Lymphoma, Follicular",
        "Malignant Lymphoma - Lymphoplasmacytic",
        "Mantle Cell Lymphoma Recurrent",
        "Marginal Zone B-Cell Lymphoma",
        "Small Lymphocytic Lymphoma",
        "T-Cell Lymphoma",
        "Waldenstrom Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "Doxycycline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2014-03",
      "completion_date": "2015-11",
      "has_results": true,
      "last_update_posted_date": "2016-12-22",
      "last_synced_at": "2026-05-16T21:58:42.995Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02086591"
    }
  ]
}